David Solomon - CEO of Pharnext - A Biopharmaceutical Company
Dr. David Solomon is the CEO of Pharnext, an advanced clinical-stage biopharmaceutical company using artificial intelligence to create therapies for rare and orphan diseases. Their first drug for Charcot-Marie-Tooth Disease (CMT1A) is in it's second pivotal Phase 3 trial. CMT1A is a rare genetic disorder of the nervous system with no current satisfactory treatment available. Dr. Solomon is committed to moving Pharnext's work on the CMT1A drug forward to bring solutions to the patients and families affected by the disease.
EPISODE HIGHLIGHTS
Share some background on your career and Pharnext.
I…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.